Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xtrana to develop nucleic acid-based chlamydia test:

This article was originally published in Clinica

Executive Summary

US company Xtrana is to develop a nucleic acid-based test for Chlamydia trachomatis using a Phase I grant from the US National Institutes of Health. The test, for use in the doctor's office or at a healthcare clinic, uses an isothermal method for amplification, eliminating the need for expensive and complex equipment such as thermocyclers, said the Denver, Colorado-based company. Xtrana added that the new test detected RNA from chlamydia and would therefore be more specific to live organisms than DNA-based tests or antibody/antigen tests.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel